Comparison of clinical features of JAK2V617F gene mutation and non-mutation in patients with Budd-Chiari syndrome
10.3760/cma.j.cn501113-20210901-00443
- VernacularTitle:JAK2V617F基因突变与非突变布-加综合征患者临床特征的对比
- Author:
Hongliang CHEN
1
;
Qingqiao ZHANG
;
Hao XU
;
Jinchang XIAO
;
Ning WEI
;
Yanfeng CUI
;
Hongtao LIU
;
Wenliang WANG
;
Maoheng. ZU
Author Information
1. 徐州医科大学附属医院介入放射科，徐州 221006
- Keywords:
Budd-Chiari syndrome;
JAK2V617F gene mutation;
Clinical characteristics
- From:
Chinese Journal of Hepatology
2022;30(12):1365-1369
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the clinical features of JAK2V617F gene mutation and non-mutation in patients with Budd-Chiari syndrome (BCS).Methods:17 and 127 BCS cases with JAK2V617F gene mutation (mutation group) and non-gene mutation (non-mutation group) who were continuously treated with interventional therapy between January 2016 to December 2020 in the Affiliated Hospital of Xuzhou Medical University were selected as the research object for a comparative study. The hospitalization and follow-up data of the two groups were analyzed retrospectively, and the deadline for follow-up was June 2021. Quantitative data group differences were analyzed using the independent sample t-test and Wilcoxon rank sum test. Qualitative data group differences were analyzed with χ2 test or Fisher's exact test. Mann-Whitney U test was used to analyze the differences between groups in rank data. Kaplan-Meier method was used to calculate the patient survival and recurrence rate. Results:Age [(35.41±17.10) years vs. (50.09±14.16) years, t=3.915, P<0.001], time of onset (median duration: 3 months vs. 12 months), and the cumulative survival rate (65.5% vs 95.1%; χ2=5.21, P=0.022) were lower in mutation than non-mutation group. Aaspartate aminotransferase, alanine aminotransferase, prothrombin time, Child-Pugh score, Rotterdam score, Model for End-stage Liver Disease score, hepatic vein thrombosis incidence, and the cumulative recurrence rate after intervention were higher in mutation than non-mutation group. The above all indexes had statistically significant differences ( P<0.05) between the groups. Conclusion:Younger age, acute onset, severe liver injury, high incidence of hepatic vein thrombosis, and poor prognosis are the features of patients with BCS with JAK2V617F gene mutation than non-mutation.
